Daily FNArena News

The company’s proposed Talecris acquisition in the US now appears unlikely to proceed but with solid earnings growth still expected brokers remain positive on the outlook for CSL.

After weeks of continuous rises the spot U3O8 price retreated the past week in the absence of any deals concluded.

Any move by the Australian government to increase its flu vaccine supplies should benefit CSL but US authorities seem ready to block the Talecris deal.

A positive trend in private health insurance membership is a good sign for private hospital operators, reports Southern Cross Equities.

ASIC has lifted the ban on short selling financial stocks in Australia.

Weekly musings from your editor. Bear market rally or not – does it really matter?

There will be a range of economic data releases from most of world’s major economies next week, while in Australia annual general meetings will further update shareholders on corporate performance.

Commonwealth Bank believes the Australian federal budget forecast of an 18.5% drop in business investment is way too panicked.

A move to better fuel economy in cars and trucks in the US may reduce gasoline demand but Barclays Capital suggests any change won’t impact on the global oil market balance.

The May survey by Westpac has in essence revealed no major changes from April about consumers’ views on unemployment or inflation.